SLC5A2 and heart failure: The results from the CANVAS study further support the effects of SGLT2 inhibitors on CV outcomes, with a significantly lower rate of the composite outcome of death from CV causes, non-fatal myocardial infarction or non-fatal stroke in the canagliflozin group, and also for the exploratory outcomes of hospitalization for heart failure, although canagliflozin did not show a significant reduction on CV mortality (18).